SCHEMBL25065713

SCHEMBL25065713

CC(C)c1cc(C(F)(F)F)nc(C(F)(F)F)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
TSHR P16473 1/20 0.62
CRHBP P24387 1/20 0.62
CRHR2 Q13324 1/20 0.62
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
TLR7 Q9NYK1 2/20 0.33
HTT P42858 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP1A2 P05177 2/20 0.31
ALDH1A1 P00352 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24848629 0.89 CYP3A4 (0.59) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL18068094 0.87 CYP3A4 (0.50) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL25930993 0.82 CYP3A4 (0.44) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL807740 0.80 CYP3A4 (0.44) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL798992 0.80 CYP2C19 (0.62) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL22767093 0.78 CYP2C19 (0.61) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL2717883 0.78 NOS3 (0.50) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL3293782 0.78 HSP90AA1 (0.43) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL20211619 0.77 CYP2C19 (1.00) CYP2C19CYP3A4CYP2D6TSHRCRHBP
SCHEMBL21212137 0.76 CYP3A4 (0.58) CYP2C19CYP3A4CYP2D6TSHRCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB, LLC 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, MPST, CRAT CYP2C19 705/4885CYP3A4 791/4885CYP2D6 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.